SVB Leerink raised the price target for the Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) stock from “a Mkt perform” to “an Outperform”. The rating was released on October 10, 2022, according to finviz. The research report from Mizuho has upgraded the stock from Neutral to Buy, with a price target set at $15. The stock was resumed by Credit Suisse, who disclosed in a research note on April 26, 2021, to Neutral and set the price objective to $6.50. In their research brief published March 02, 2021, Credit Suisse analysts upgraded the Satsuma Pharmaceuticals Inc. stock from Underperform to Neutral with a price target of $6.50.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) raised 10.40% to close Monday’s market session at $0.72, higher as compared to yesterday’s close. The stock price fluctuated between $0.6301 and $0.74 throughout the trading session with the volume trading being 4702434 shares, which represented a significant variation when compared to the three months average volume of 621.60K shares. The firm’s stock price fluctuated 5.61% within the last five trades and -86.81% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -77.58% in the last 6 months and -88.08% was subtracted to its value over the previous 3 months. STSA stock is trading at a margin of -80.73%, -86.23% and -84.25% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
As of the close of trading, STSA deals in the Healthcare domain. The stock is trading -91.12 percent below its 52-week high and 21.63 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -45.23. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Satsuma Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $22.63 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 0.33, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 9.98 percent of Satsuma Pharmaceuticals Inc. shares are owned by insiders, and 74.40 percent are held by financial institutions. Leonard Braden Michael, the 10% Owner at Satsuma Pharmaceuticals Inc. (STSA) has bought 831,694 shares of firm on Nov 15 at a price of $0.63 against the total amount of $0.53 million. In another inside trade, Leonard Braden Michael, 10% Owner of Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) bought 5,608,306 shares of the firm on Nov 14 for a total worth of $3.87 million at a price of $0.69. An inside trade which took place on Nov 14, 10% Owner of Satsuma Pharmaceuticals Inc. COMMODORE CAPITAL LP sold 3,250,000 shares of firm against total price of $2.29 million at the cost of $0.71 per share.